OSI Pharmaceuticals Initiates Phase III Clinical Trial for Tarceva in NSCLC Patients

Strategic Insights -

OSI Pharmaceuticals, Inc. has started a Phase III clinical trial of Tarceva (erlotinib) as a targeted adjuvant therapy in patients who have undergone surgery for non-small cell lung cancer (NSCLC) with EGFR-positive tumors. This study aims to evaluate the effectiveness of adjuvant therapy with Tarceva in prolonging disease-free survival in approximately 945 patients. The trial will compare the outcomes of patients receiving Tarceva with those receiving a placebo, with a primary objective of assessing disease-free survival and secondary objectives including overall survival, safety, and the prognostic value of EGFR-related biomarkers.

Key Takeaways:

  • OSI Pharmaceuticals has initiated a Phase III clinical trial of Tarceva (erlotinib) as a targeted adjuvant therapy in patients with NSCLC and EGFR-positive tumors.
  • The study will enroll approximately 945 patients with surgically removed Stage IB-IIIA NSCLC who have completed up to four cycles of standard adjuvant platinum-based chemotherapy or are chemotherapy naive.
  • Patients will be randomized 2:1 to receive either Tarceva 150 mg or placebo once daily for two years.
  • The primary objective of the study is to evaluate the effectiveness of adjuvant therapy with Tarceva in prolonging disease-free survival.
  • Secondary objectives include comparing overall survival, evaluating the safety of adjuvant Tarceva therapy, and exploring the prognostic value of EGFR-related biomarkers.

Statistics:

  • 945 patients will be enrolled in the Phase III clinical trial.
  • The trial will randomize patients 2:1 to receive either Tarceva 150 mg or placebo once daily for two years.
  • The study will last for two years.

Sources:

  • Health & Medicine Week editors from staff and other reports, 2006, Copyright 2006, Health & Medicine Week via NewsRx.com.